Ron Smits
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ron Smits has a total of 291 co-authors. Here are the top co-authors by number of shared publications:
- Maikel Petrus Peppelenbosch
Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands
66 shared publications - Ruyi Zhang
Yunnan Key Laboratory of Chiral Functional Substance Research and Application, Yunnan Minzu University, No. 2929, Yuehua Street, Chenggong District, Kunming 650504, China
54 shared publications - Xin Chen
Cancer Biology Program, University of Hawaii Cancer Center, Honolulu, USA
54 shared publications - Boaz Eimers
Department of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands
53 shared publications - Guofei Cui
Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California
53 shared publications - Joyce H. G. Lebbink
Department of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA, Rotterdam, The Netherlands; Department of Radiotherapy, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA, Rotterdam, the Netherlands
53 shared publications
Latest Publications
- Open Access
Reassessment of RNF43 Function Reveals No Impact on Endogenous EGFR or BRAF Protein Stability
RNF43 is best known for removing the Wnt-receptor complex from the cell surface, thereby maintaining Wnt-signaling at minimal essential levels. Recent studies reported that RNF43-mutant colorectal cancers carrying the common BRAFV600E mutation, respond more effectively to combined BRAF/EGFR inhibition. To determine whether RNF43 directly regulates EGFR or BRAF protein abundance, multiple pancreatic and colorectal cancer cell line models were generated in which RNF43 was knocked out, repaired, or stably overexpressed. Total and cell surface EGFR levels, as well as endogenous BRAF expression, were quantified. Across all models, no consistent evidence emerges that RNF43 modulates endogenous EGFR or BRAF levels. R-spondins likewise fail to alter EGFR levels or internalization. Notably, elevated EGFR expression observed in a subset of RNF43 knockout clones is induced by unintended CRISPR/Cas9 vector integration rather than the absence of RNF43 itself, highlighting a previously underappreciated artefact that can confound interpretations of EGFR regulation in genome edited lines. Overall, the data argue against a direct and general role for RNF43 in controlling EGFR or BRAF protein abundance, contradicting recent reports that propose degradation of these targets. Further studies are required to resolve these discrepancies and clarify the mechanistic basis underlying these conflicting observations.
Open AccessReassessment of RNF43 Function Reveals No Impact on Endogenous EGFR or BRAF Protein Stability
RNF43 is best known for removing the Wnt-receptor complex from the cell surface, thereby maintaining Wnt-signaling at minimal essential levels. Recent studies reported that RNF43-mutant colorectal cancers carrying the common BRAFV600E mutation, respond more effectively to combined BRAF/EGFR inhibition. To determine whether RNF43 directly regulates EGFR or BRAF protein abundance, multiple pancreatic and colorectal cancer cell line models were generated in which RNF43 was knocked out, repaired, or stably overexpressed. Total and cell surface EGFR levels, as well as endogenous BRAF expression, were quantified. Across all models, no consistent evidence emerges that RNF43 modulates endogenous EGFR or BRAF levels. R-spondins likewise fail to alter EGFR levels or internalization. Notably, elevated EGFR expression observed in a subset of RNF43 knockout clones is induced by unintended CRISPR/Cas9 vector integration rather than the absence of RNF43 itself, highlighting a previously underappreciated artefact that can confound interpretations of EGFR regulation in genome edited lines. Overall, the data argue against a direct and general role for RNF43 in controlling EGFR or BRAF protein abundance, contradicting recent reports that propose degradation of these targets. Further studies are required to resolve these discrepancies and clarify the mechanistic basis underlying these conflicting observations.
- Open Access
- 14 December 2024
- Published by Springer Nature in Oncogene
- Vol. 44 (12) , 805-819
Lack of dominant-negative activity for tumor-related ZNRF3 missense mutations at endogenous levels
ZNRF3, a negative regulator of β-catenin signaling, removes Wnt receptors from the membrane. Currently, it is unknown which tumor-associated variants can be considered driver mutations and through which mechanisms they contribute to cancer. Here we show that all truncating mutations analyzed at endogenous levels exhibit loss-of-function, with longer variants retaining partial activity. Regarding missense mutations, we show that 27/82 ZNRF3 variants in the RING and R-Spondin domain structures, lead to (partial) loss-of-function/hyperactivation. Mechanistically, defective R-Spondin domain variants appear to undergo endoplasmic-reticulum-associated degradation due to protein misfolding, leading to reduced protein levels. They fail to reach the membrane correctly, which can be partially restored for several variants by culturing cells at 27 °C. Although RING and R-Spondin domain mutations in RNF43/ZNRF3 are often considered to possess dominant-negative oncogene-like activity in cancers, our findings challenge this notion. When representative variants are heterozygously introduced into endogenous ZNRF3, their impact on β-catenin signaling mirrors that of heterozygous knockout, suggesting that the supposed dominant-negative effect is non-existent. In other words, so-called “hyperactivating” ZNRF3/RNF43 mutations behave as classical loss-of-function mutations at endogenous levels.
- 14 December 2024
- Published by Springer Nature in Oncogene
- Vol. 44 (12) , 805-819
Open AccessLack of dominant-negative activity for tumor-related ZNRF3 missense mutations at endogenous levels
ZNRF3, a negative regulator of β-catenin signaling, removes Wnt receptors from the membrane. Currently, it is unknown which tumor-associated variants can be considered driver mutations and through which mechanisms they contribute to cancer. Here we show that all truncating mutations analyzed at endogenous levels exhibit loss-of-function, with longer variants retaining partial activity. Regarding missense mutations, we show that 27/82 ZNRF3 variants in the RING and R-Spondin domain structures, lead to (partial) loss-of-function/hyperactivation. Mechanistically, defective R-Spondin domain variants appear to undergo endoplasmic-reticulum-associated degradation due to protein misfolding, leading to reduced protein levels. They fail to reach the membrane correctly, which can be partially restored for several variants by culturing cells at 27 °C. Although RING and R-Spondin domain mutations in RNF43/ZNRF3 are often considered to possess dominant-negative oncogene-like activity in cancers, our findings challenge this notion. When representative variants are heterozygously introduced into endogenous ZNRF3, their impact on β-catenin signaling mirrors that of heterozygous knockout, suggesting that the supposed dominant-negative effect is non-existent. In other words, so-called “hyperactivating” ZNRF3/RNF43 mutations behave as classical loss-of-function mutations at endogenous levels.
- Open Access
- 17 November 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1879 (6) , 189217
RNF43 and ZNRF3: Versatile regulators at the membrane and their role in cancer
- 17 November 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1879 (6) , 189217
Open AccessRNF43 and ZNRF3: Versatile regulators at the membrane and their role in cancer
- Open Access
- 7 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0304607
Unraveling the impact of AXIN1 mutations on HCC development: Insights from CRISPR/Cas9 repaired AXIN1-mutant liver cancer cell lines
Background: Hepatocellular carcinoma (HCC) is a highly aggressive liver cancer with significant morbidity and mortality rates. AXIN1 is one of the top-mutated genes in HCC, but the mechanism by which AXIN1 mutations contribute to HCC development remains unclear. Methods: In this study, we utilized CRISPR/Cas9 genome editing to repair AXIN1-truncated mutations in five HCC cell lines. Results: For each cell line we successfully obtained 2–4 correctly repaired clones, which all show reduced β-catenin signaling accompanied with reduced cell viability and colony formation. Although exposure of repaired clones to Wnt3A-conditioned medium restored β-catenin signaling, it did not or only partially recover their growth characteristics, indicating the involvement of additional mechanisms. Through RNA-sequencing analysis, we explored the gene expression patterns associated with repaired AXIN1 clones. Except for some highly-responsive β-catenin target genes, no consistent alteration in gene/pathway expression was observed. This observation also applies to the Notch and YAP/TAZ-Hippo signaling pathways, which have been associated with AXIN1-mutant HCCs previously. The AXIN1-repaired clones also cannot confirm a recent observation that AXIN1 is directly linked to YAP/TAZ protein stability and signaling. Conclusions: Our study provides insights into the effects of repairing AXIN1 mutations on β-catenin signaling, cell viability, and colony formation in HCC cell lines. However, further investigations are necessary to understand the complex mechanisms underlying HCC development associated with AXIN1 mutations.
- 7 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0304607
Open AccessUnraveling the impact of AXIN1 mutations on HCC development: Insights from CRISPR/Cas9 repaired AXIN1-mutant liver cancer cell lines
Background: Hepatocellular carcinoma (HCC) is a highly aggressive liver cancer with significant morbidity and mortality rates. AXIN1 is one of the top-mutated genes in HCC, but the mechanism by which AXIN1 mutations contribute to HCC development remains unclear. Methods: In this study, we utilized CRISPR/Cas9 genome editing to repair AXIN1-truncated mutations in five HCC cell lines. Results: For each cell line we successfully obtained 2–4 correctly repaired clones, which all show reduced β-catenin signaling accompanied with reduced cell viability and colony formation. Although exposure of repaired clones to Wnt3A-conditioned medium restored β-catenin signaling, it did not or only partially recover their growth characteristics, indicating the involvement of additional mechanisms. Through RNA-sequencing analysis, we explored the gene expression patterns associated with repaired AXIN1 clones. Except for some highly-responsive β-catenin target genes, no consistent alteration in gene/pathway expression was observed. This observation also applies to the Notch and YAP/TAZ-Hippo signaling pathways, which have been associated with AXIN1-mutant HCCs previously. The AXIN1-repaired clones also cannot confirm a recent observation that AXIN1 is directly linked to YAP/TAZ protein stability and signaling. Conclusions: Our study provides insights into the effects of repairing AXIN1 mutations on β-catenin signaling, cell viability, and colony formation in HCC cell lines. However, further investigations are necessary to understand the complex mechanisms underlying HCC development associated with AXIN1 mutations.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate β-Catenin Signaling
The AXIN1 mutation landscape for various cancer types
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate β-Catenin Signaling
The AXIN1 mutation landscape for various cancer types
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 16 from Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate β-Catenin Signaling
Strong AXIN1 missense variants induce liver tumor formation in mice
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 16 from Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate β-Catenin Signaling
Strong AXIN1 missense variants induce liver tumor formation in mice
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 15 from Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate β-Catenin Signaling
Side-by-side comparison of selected AXIN1 variants in different domains
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 15 from Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate β-Catenin Signaling
Side-by-side comparison of selected AXIN1 variants in different domains
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate β-Catenin Signaling
Additional analysis of missense variants near the GSK3β domain
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate β-Catenin Signaling
Additional analysis of missense variants near the GSK3β domain
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate β-Catenin Signaling
AlphaFold structure prediction for human AXIN1
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate β-Catenin Signaling
AlphaFold structure prediction for human AXIN1